Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
March 07 2017 - 5:05PM
Business Wire
Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that
it has priced an offering of €500 million aggregate principal
amount of 1.450% senior notes due 2027 at an issue price of 98.824%
of the principal amount.
The issuance of the notes is expected to close on or about March
16, 2017, subject to customary closing conditions. The notes will
pay interest on an annual basis.
Thermo Fisher intends to use approximately $508 million of the
net proceeds of the offering to redeem all of the outstanding $500
million aggregate principal amount of its 1.850% senior notes that
mature on January 15, 2018 and to pay accrued interest, fees and
expenses associated with the redemption. Thermo Fisher intends to
use any remaining net proceeds for general corporate purposes.
The joint book-running managers for the offering are Credit
Suisse Securities (Europe) Limited and HSBC Bank plc.
The offering is being made pursuant to an effective registration
statement on Form S-3, as amended by the post-effective amendment
thereto (including a prospectus), filed with the U.S. Securities
and Exchange Commission (the “SEC”). Prospective investors should
read the prospectus forming a part of that registration statement
and the prospectus supplement related to the offering and the other
documents that the company has filed with the SEC for more complete
information about the company and this offering. These documents
are available at no charge by visiting EDGAR on the SEC website at
www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any
dealer participating in this offering will arrange to send you the
prospectus if you request it by calling Credit Suisse Securities
(Europe) Limited toll-free at 1-800-221-1037, or by calling HSBC
Bank plc toll-free at 1-866-811-8049.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any
offer, solicitation or sale of the notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about the company’s
intended use of proceeds. These statements involve a number of
risks and uncertainties that could cause actual results to differ
materially from currently anticipated results, including risks and
uncertainties relating to capital markets conditions and completion
of the offering. Additional important factors and information
regarding Thermo Fisher’s business that could cause actual results
to differ materially from those indicated by such forward-looking
statements are set forth in the prospectus and prospectus
supplement dated March 7, 2017 related to the offering, which is on
file with the SEC and available in the “Investors” section of our
website under the heading “SEC Filings,” and the documents
incorporated by reference into the prospectus and prospectus
supplement. While we may elect to update forward-looking statements
at some point in the future, we specifically disclaim any
obligation to do so, even if circumstances change and, therefore,
you should not rely on these forward-looking statements as
representing our views as of any date subsequent to today.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170307006486/en/
Thermo Fisher Scientific Inc.Media Contact Information:Karen
Kirkwood, 781-622-1306karen.kirkwood@thermofisher.comorInvestor
Contact Information:Ken Apicerno,
781-622-1294ken.apicerno@thermofisher.com
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Sep 2023 to Sep 2024